Home › NDC Lookup › RxCUI directory › RxCUI 1092357

Rufinamide 40 MG/ML Oral Suspension — RxCUI 1092357

RxNorm drug concept · Semantic clinical drug
RxCUI 1092357 Semantic clinical drug · SCD ● Current RxNorm concept 12 FDA products 14 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1092357
Official nameRufinamide 40 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asrufinamide 40 MG per 1 ML Oral Suspension; rufinamide 40 MG in 1 mL Oral Suspension; rufinamide 400 MG per 10 ML Oral Suspension
FDA products mapped12
Package NDCs mapped14
Reported Medicaid activity (SDUD)37,354 prescriptions · 44 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Rufinamide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Rufinamide — sold as Banzel — is used to help control seizures in people with Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that often starts in childhood. It's always u...
  • Yes — this one really matters. Food significantly increases how much rufinamide your body absorbs, so taking it on an empty stomach means you could be getting much less of the medi...
  • Do I really need to take it with food every time?
  • The most common ones are drowsiness, headache, dizziness, nausea or vomiting, and feeling tired — these are annoying but generally manageable. The ones that need a call to your doc...
📖 Read our full Rufinamide guide →

🕸️ Concept Web — How Rufinamide 40 MG/ML Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Rufinamide 40 MG/ML Oral Suspension RxCUI 1092357

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Rufinamide 69036
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Banzel 824296
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Rufinamide Oral Suspension 1092356
    • Rufinamide Oral Liquid Product 1157999
    • Rufinamide Oral Product 1158000
    • Rufinamide Oral Suspension [Banzel] 1092359
    • Banzel Oral Liquid Product 1168001
    • Banzel Oral Product 1168002
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Rufinamide 40 MG/ML SCDC · 1092355
  • Rufinamide Oral Suspension SCDF · 1092356
  • Rufinamide Oral Liquid Product SCDG · 1157999
  • Rufinamide Oral Product SCDG · 1158000

Brand-Name Concepts

  • Rufinamide 40 MG/ML Oral Suspension [Banzel] SBD · 1092360
  • Rufinamide 40 MG/ML [Banzel] SBDC · 1092358
  • Rufinamide Oral Suspension [Banzel] SBDF · 1092359
  • Banzel Oral Liquid Product SBDG · 1168001
  • Banzel Oral Product SBDG · 1168002
  • Banzel BN · 824296

📦 FDA Products & Package NDCs

12 products · 14 package NDCs
14 package NDCs map to RxCUI 1092357 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00054-0528-63 1 BOTTLE in 1 CARTON (0054-0528-63) / 460 mL in 1 BOTTLE Rufinamide Hikma Pharmaceuticals USA Inc. 2020-11-01
31722-0688-46 1 BOTTLE in 1 CARTON (31722-688-46) / 460 mL in 1 BOTTLE Rufinamide Camber Pharmaceuticals, Inc. 2023-12-05
59651-0563-60 1 BOTTLE in 1 CARTON (59651-563-60) / 460 mL in 1 BOTTLE RUFINAMIDE Aurobindo Pharma Limited 2022-10-26
60687-0824-08 3 TRAY in 1 CASE (60687-824-08) / 10 CUP, UNIT-DOSE in 1 TR... Rufinamide American Health Packaging 2026-01-06
62856-0582-04 4 TABLET, FILM COATED in 1 BOTTLE (62856-582-04) Banzel Eisai Inc. 2018-08-08
62856-0582-52 120 TABLET, FILM COATED in 1 BOTTLE (62856-582-52) Banzel Eisai Inc. 2008-11-14
62856-0583-14 14 TABLET, FILM COATED in 1 BOTTLE (62856-583-14) Banzel Eisai Inc. 2018-08-08
62856-0583-52 120 TABLET, FILM COATED in 1 BOTTLE (62856-583-52) Banzel Eisai Inc. 2008-11-14
62856-0584-46 1 BOTTLE in 1 CARTON (62856-584-46) / 460 mL in 1 BOTTLE Banzel Eisai Inc. 2011-03-03
67877-0673-62 1 BOTTLE in 1 CARTON (67877-673-62) / 460 mL in 1 BOTTLE Rufinamide Ascend Laboratories, LLC 2021-02-24
68180-0797-01 1 BOTTLE in 1 CARTON (68180-797-01) / 460 mL in 1 BOTTLE Rufinamide Lupin Pharmaceuticals, Inc. 2023-06-22
69452-0223-84 1 BOTTLE in 1 CARTON (69452-223-84) / 460 mL in 1 BOTTLE Rufinamide Bionpharma Inc. 2020-11-06
72205-0038-77 1 BOTTLE in 1 CARTON (72205-038-77) / 460 mL in 1 BOTTLE Rufinamide Novadoz Pharmaceuticals LLC 2025-06-01
72603-0261-01 1 BOTTLE in 1 CARTON (72603-261-01) / 460 mL in 1 BOTTLE Rufinamide NorthStar RxLLC 2024-08-01
Observed labelers: Eisai Inc. (5) · American Health Packaging (1) · Ascend Laboratories, LLC (1) · Aurobindo Pharma Limited (1) · Bionpharma Inc. (1) · Camber Pharmaceuticals, Inc. (1) · +4 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.